GSK raises margin outlook, plots $2.5 billion restructuring to fast-track new drugs
--------------------------------------------------------------------
Source: The Manila Times
Published: 2026-07-30 19:01 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Science, Health, Property, Europe, Drugs, Business & Economy
--------------------------------------------------------------------
Snippet:
LONDON — GSK launched a 1.9 billion pounds ($2.52 billion) cost-savings effort on Tuesday to help fund the British drugmaker’s expanded late-stage study roster, as CEO Luke Miels works to deliver on his promise of faster drug development.
--------------------------------------------------------------------